PRTK
Paratek Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Nov. 2, 7:39 AM
    | Wed, Nov. 2, 7:39 AM | 8 Comments
  • Fri, Oct. 28, 12:40 PM
    • Cidara Therapeutics (NASDAQ:CDTX) initiated with Buy rating by Cantor Fitzgerald.
    • Ohr Pharmaceuticals (NASDAQ:OHRP) initiated with Buy rating and $10 (223% upside) price target by H.C. Wainwright.
    • Sarepta Therapeutics (NASDAQ:SRPT) initiated with Equal Weight rating and $53 (28% upside) price target by Morgan Stanley.
    • AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Buy rating and $40 (58% upside) price target by Needham.
    • Nabriva Therapeutics (NASDAQ:NBRV) initiated with Outperform rating and $14 (138% upside) price target by Leerink Swann.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) initiated with Outperform rating and $23 (107% upside) price target by Leerink Swann.
    • Glaukos (NYSE:GKOS) initiated with Outperform rating and $42 (midpoint) (26% upside) price target by Wells Fargo.
    • Calithera Biosciences (NASDAQ:CALA) initiated with Sell rating and $1 (62% downside risk) price target by Citigroup.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (173% upside) price target by Aegis Capital.
    • Clovis Oncology (NASDAQ:CLVS) initiated with Sell rating and $15 (50% downside risk) price target by Chardan Capital.
    • Fulgent Genetics (Pending:FLGT) initiated with Overweight rating and $13 (42% upside) price target by Piper Jaffray. Initiated with Buy rating and $15 (64% upside) price target by BTIG Research.
    • Tabula Rosa Healthcare (Pending:TRHC) initiated with Outperform rating and $17 (38% upside) price target by Wells Fargo.
    • Xenon Pharmaceuticals (NASDAQ:XENE) initiated with Buy rating and $18 (121% upside) price target by Stifel Nicolaus.
    | Fri, Oct. 28, 12:40 PM | 2 Comments
  • Thu, Aug. 4, 7:11 AM
    • Paratek Pharmaceuticals (NASDAQ:PRTK): Q2 EPS of -$1.69
    • Cash and cash equivalents of $150.4M.
    • Press Release
    | Thu, Aug. 4, 7:11 AM | 1 Comment
  • Wed, Jun. 22, 8:21 AM
    • Thinly traded micro cap Paratek Pharmaceutics (NASDAQ:PRTK) inches up 2% premarket on increased volume after the company announced that it has priced its public offering of 4.25M shares of common stock at $13 a share. Underwriters over-allotment is an additional 637.5K shares. Net proceeds should be ~$51.4M. Closing date is June 27.
    | Wed, Jun. 22, 8:21 AM
  • Tue, Jun. 21, 12:48 PM
    | Tue, Jun. 21, 12:48 PM | 12 Comments
  • Tue, Jun. 21, 11:00 AM
    | Tue, Jun. 21, 11:00 AM | 1 Comment
  • Fri, Jun. 17, 11:00 AM
    | Fri, Jun. 17, 11:00 AM | 11 Comments
  • Fri, Jun. 17, 9:14 AM
    | Fri, Jun. 17, 9:14 AM
  • Thu, Jun. 16, 4:48 PM
    • A Phase 3 clinical trial, OASIS, evaluating Paratek Pharmaceuticals' (NASDAQ:PRTK) omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) met all efficacy endpoints.
    • The 645-subject study assessed IV-to-oral once-daily omadacycline compared to twice daily linezolid [Pfizer's (NYSE:PFE) ZYVOX] over a 7-14-day course of therapy.
    • The primary endpoint for the FDA was Early Clinical Response (ECR) at 48-72 hours after the first dose in the modified Intent-to-Treat population (mITT) (patients without an infection that could be caused by a single species of Gram-negative bacteria). In this group, omadacycline was shown to be non-inferior (no worse than) to linezolid. The ECR for each medication was 84.8% and 85.5%, respectively.
    • The co-primary endpoints for the European Medicines Agency were an assessment of clinical response at the post-treatment evaluation (PTE) in the mITT and clinically evaluable (CE) populations. In both groups, omadacycline again demonstrated non-inferiority to linezolid. In the mITT population at PTE, the clinical success rates for omadacycline and linezolid were 86.1% and 83.6%, respectively. In the CE population at PTE, the clinical success rates were 96.3% and 93.5%, respectively. Omadacycline showed comparable clinical success rates to linezolid across the most common ABSSSI pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    • Treatment-emergent adverse events were similar between the two groups. The most common were gastrointestinal events (18.0% for omadacycline vs. 15.8% for linezolid), including nausea (12.4% vs. 9.9%) and vomiting (5.3% vs. 5.0%).
    • Omadacycline, a tetracycline antibiotic known as an aminomethylcycline, has broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
    • OASIS is the first of two pivotal studies that will support regulatory applications in the U.S. and Europe.
    • Complete results will be presented at an upcoming scientific conference.
    • Shares are up 18% after hours on robust volume.
    | Thu, Jun. 16, 4:48 PM | 7 Comments
  • Mon, May 2, 4:55 PM
    • Paratek Pharmaceuticals (NASDAQ:PRTK): Q1 EPS of -$1.78.
    | Mon, May 2, 4:55 PM
  • Mon, Apr. 4, 12:49 PM
    | Mon, Apr. 4, 12:49 PM
  • Fri, Mar. 4, 9:15 AM
    • BeiGene (NASDAQ:BGNE) initiated with Overweight rating and $39 (22% upside) price target by Morgan Stanley. Initiated with Outperform rating by Cowen & Co.
    • Editas Medicine (NASDAQ:EDIT) initiated with Outperform rating and $40 (7% upside) price target by JMP Securities.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) initiated with Buy rating and $32 (100% upside) price target by H.C. Wainwright.
    | Fri, Mar. 4, 9:15 AM
  • Tue, Feb. 23, 7:04 AM
    • Paratek Pharmaceuticals (NASDAQ:PRTK): Q4 EPS of -$1.20
    | Tue, Feb. 23, 7:04 AM
  • Wed, Jan. 6, 11:49 AM
    | Wed, Jan. 6, 11:49 AM
  • Nov. 12, 2015, 9:44 AM
    • Paratek Pharmaceuticals (PRTK -3.2%) Q3 results: Revenues: $0; R&D Expense: $17.8M (+999%); SG&A: $5.8M (+176.2%); Net Loss: ($23.4M) (-485.0%); Loss Per Share: ($1.33) (+95.5%); Quick Assets: $146.4M (+52.7%).
    • No guidance given.
    | Nov. 12, 2015, 9:44 AM
  • Nov. 12, 2015, 7:03 AM
    • Paratek Pharmaceuticals (NASDAQ:PRTK): Q3 EPS of -$1.33
    | Nov. 12, 2015, 7:03 AM